Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
28 February, 2021 08:35 IST
IDBI Capital reiterates Buy rating on ICICI Bank; target price of Rs 670
Source: IRIS | 06 Feb, 2021, 09.13AM
Rating: NAN / 5 stars.
Comments  |  Post Comment


ICICI Bank (one of our top picks) reported strong set of numbers with a) stable asset quality (Proforma), b) Restructured book at 0.4% and c) PAT growth at 19% YoY (up 16% QoQ) during toughest quarter Q3FY21. Asset quality on Proforma basis remains stable with GNPA at 5.42% versus 5.36% QoQ; however slippage ratio was higher on sequential basis, said IDBI Capital in its research report.

Restructuring under RBI resolution framework stood at 0.5% of advances, including corporate cases and company guided for less than 1% of advances for FY21. Management said collection efficiency has improved during Q3FY21 versus 97% of pre-covid levels for retail portfolio (Q2FY21). NII grew by 16% YoY against a loan growth of 10% YoY; margins improved sequentially. PPoP grew by 17% YoY as cost to income ratio improved (40% vs 42.5% YoY). Strong liability franchise and higher Tier I capital ratio will advantage bank when the economy growth recovers, it added.

"We re-iterate "Buy" with a new TP of Rs. 670 (earlier Rs.580), valuing parent business at Rs.547 (2.1X P/ABV FY23E vs earlier at 1.8X as Covid impact was lower than estimated) and rest for the subsidiaries," the broking firm stated.

Disclaimer: IRIS has taken due care and caution in compilation of data for its web site. Information has been obtained by IRIS from sources which it considers reliable. However, IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website.

 Post Comment
Name Email
Security Code type    into this box
Company Update
DHFL files resolution plan application with NCLT - 26-Feb-2021 14:29
Hero Xpulse 200 crosses landmark 10,000 sales in Kerala - 26-Feb-2021 14:00
Natco Pharma launches Brivaracetam tablets in India - 26-Feb-2021 13:42
Buy NTPC; target price of Rs 141: Motilal Oswal - 26-Feb-2021 12:13
IRB Infrastructure Developers allots NCDs aggregating Rs 21,845.5 mn - 26-Feb-2021 10:22
IRB Infrastructure subsidiary completes Thane Ghodbunder BOT project - 26-Feb-2021 10:06
Sun Pharma launches website for its long-term care division - 26-Feb-2021 09:52
Glenmark receives 'India Pharma Innovation of the Year' award - 26-Feb-2021 09:10
APL Apollo Tubes allots Commercial Papers worth Rs 750 mn - 26-Feb-2021 08:09
HAP starts commercial production at its new Maharashtra plant - 25-Feb-2021 19:38
Gujarat Alkalies enters into agreement for availing ECB facility - 25-Feb-2021 18:18
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer